[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @m72068958 다율잉(DaYule) 다율잉(DaYule) posts on X about $crsp, vivo, $ntla, $prme the most. They currently have XX followers and XX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::1310244506969583617/interactions)  - X Week XXX -XX% - X Months XXXXX -XX% - X Year XXXXXX +964% ### Mentions: X [#](/creator/twitter::1310244506969583617/posts_active)  - X Week X no change - X Months X -XX% - X Year XX +329% ### Followers: XX [#](/creator/twitter::1310244506969583617/followers)  - X Week XX -XXXX% - X Months XX +23% ### CreatorRank: undefined [#](/creator/twitter::1310244506969583617/influencer_rank)  ### Social Influence [#](/creator/twitter::1310244506969583617/influence) --- **Social category influence** [technology brands](/list/technology-brands) XXXXX% **Social topic influence** [$crsp](/topic/$crsp) #34, [vivo](/topic/vivo) 14.29%, [$ntla](/topic/$ntla) 7.14%, [$prme](/topic/$prme) 7.14%, [$xbi](/topic/$xbi) 7.14%, [targets](/topic/targets) 7.14%, [rat](/topic/rat) 7.14%, [humans](/topic/humans) XXXX% **Top accounts mentioned or mentioned by** [@crsp](/creator/undefined) **Top assets mentioned** [CRISPR Therapeutics AG (CRSP)](/topic/$crsp) [Intellia Therapeutics, Inc (NTLA)](/topic/$ntla) [Bitcoin Incognito (XBI)](/topic/$xbi) ### Top Social Posts [#](/creator/twitter::1310244506969583617/posts) --- Top posts by engagements in the last XX hours "Who am I A gene-editing company shareholder. I am $NTLA I am $PRME I am $CRSP I am $XBI" [X Link](https://x.com/m72068958/status/1976031149899252208) [@m72068958](/creator/x/m72068958) 2025-10-08T21:05Z XX followers, 1016 engagements "1. Big moment for $CRSP. CRISPR Therapeutics just presented new preclinical data for CTX460 the first candidate from its SyNTase gene editing platform at #ESGCT2025. It targets Alpha-1 Antitrypsin Deficiency (AATD) a rare liver & lung disease with no curative options" [X Link](https://x.com/m72068958/status/1976619928737435660) [@m72068958](/creator/x/m72068958) 2025-10-10T12:04Z XX followers, XXX engagements "Whats special: CTX460 achieved XX% mRNA correction X increase in total AAT and XX% M-AAT:Z-AAT ratio in disease models all from a single intravenous dose. Thats potentially best-in-class efficacy for an in vivo editing therapy. $CRSP" [X Link](https://x.com/m72068958/status/1976620025751744804) [@m72068958](/creator/x/m72068958) 2025-10-10T12:05Z XX followers, XXX engagements "$CRSP CTX460 uses a SyNTase editor delivered via a lipid nanoparticle (LNP) No viral vector no double-strand breaks. It directly corrects the E342K mutation in SERPINA1 restoring normal alpha-1 antitrypsin protein levels in hepatocytes" [X Link](https://x.com/m72068958/status/1976620174200758473) [@m72068958](/creator/x/m72068958) 2025-10-10T12:05Z XX followers, XXX engagements "$CRSP Preclinical data in mouse and rat AATD models showed: Near-saturating DNA correction at XXX mg/kg Durable effect for up to X weeks Linear correlation between editing efficiency and AAT restoration Proof-of-concept achieved for one-time in vivo gene correction" [X Link](https://x.com/m72068958/status/1976620256375476279) [@m72068958](/creator/x/m72068958) 2025-10-10T12:06Z XX followers, XXX engagements "$CRSP The first SyNTase-based program will enter the clinic mid-2026. If validated in humans this could redefine the treatment landscape not only for AATD but also for a broad class of liver and metabolic diseases" [X Link](https://x.com/m72068958/status/1976620323853517240) [@m72068958](/creator/x/m72068958) 2025-10-10T12:06Z XX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@m72068958 다율잉(DaYule)
다율잉(DaYule) posts on X about $crsp, vivo, $ntla, $prme the most. They currently have XX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXX -XX%
- X Months XXXXX -XX%
- X Year XXXXXX +964%
Mentions: X #
- X Week X no change
- X Months X -XX%
- X Year XX +329%
Followers: XX #
- X Week XX -XXXX%
- X Months XX +23%
CreatorRank: undefined #
Social Influence #
Social category influence technology brands XXXXX%
Social topic influence $crsp #34, vivo 14.29%, $ntla 7.14%, $prme 7.14%, $xbi 7.14%, targets 7.14%, rat 7.14%, humans XXXX%
Top accounts mentioned or mentioned by @crsp
Top assets mentioned CRISPR Therapeutics AG (CRSP) Intellia Therapeutics, Inc (NTLA) Bitcoin Incognito (XBI)
Top Social Posts #
Top posts by engagements in the last XX hours
"Who am I A gene-editing company shareholder. I am $NTLA I am $PRME I am $CRSP I am $XBI"
X Link @m72068958 2025-10-08T21:05Z XX followers, 1016 engagements
"1. Big moment for $CRSP. CRISPR Therapeutics just presented new preclinical data for CTX460 the first candidate from its SyNTase gene editing platform at #ESGCT2025. It targets Alpha-1 Antitrypsin Deficiency (AATD) a rare liver & lung disease with no curative options"
X Link @m72068958 2025-10-10T12:04Z XX followers, XXX engagements
"Whats special: CTX460 achieved XX% mRNA correction X increase in total AAT and XX% M-AAT:Z-AAT ratio in disease models all from a single intravenous dose. Thats potentially best-in-class efficacy for an in vivo editing therapy. $CRSP"
X Link @m72068958 2025-10-10T12:05Z XX followers, XXX engagements
"$CRSP CTX460 uses a SyNTase editor delivered via a lipid nanoparticle (LNP) No viral vector no double-strand breaks. It directly corrects the E342K mutation in SERPINA1 restoring normal alpha-1 antitrypsin protein levels in hepatocytes"
X Link @m72068958 2025-10-10T12:05Z XX followers, XXX engagements
"$CRSP Preclinical data in mouse and rat AATD models showed: Near-saturating DNA correction at XXX mg/kg Durable effect for up to X weeks Linear correlation between editing efficiency and AAT restoration Proof-of-concept achieved for one-time in vivo gene correction"
X Link @m72068958 2025-10-10T12:06Z XX followers, XXX engagements
"$CRSP The first SyNTase-based program will enter the clinic mid-2026. If validated in humans this could redefine the treatment landscape not only for AATD but also for a broad class of liver and metabolic diseases"
X Link @m72068958 2025-10-10T12:06Z XX followers, XXX engagements